1Ekstrom p,Carling L,Unge P,et al.Lansoprazole versus omeprazole in active duodenal ulcer:a duoble blind,randomised comparative study.Scand J Gastroenterol,1995,30:210.
2Simon A,Besamon M,Shin J M,et al.The ase sites that react selectively with the benzinidazol class of anti-ulcer drugs.Gastroenterology,1993,104(part2):A192.
3Simon WA,Budingen C,Fahr S,et al.The H+/K+-ATPase inhibitor pantoprazole(BY1023/SK&F96022)interacts less with cytochrome P450 than omeprazole and lansoprazole.Bioche m Pharmocol,1991,42(2):347.
4Tucher GT.The interaction of proton pump inhibitors with cytochromes P450.Aliment Pharmacol Ther,1994,8(Suppl 1):S33.
5Bader JP,Delchier JC.Clinical efficacy of pantoprazole compared with ranitidine.Aliment Pharmacol Ther.1994,8(Suppl 1):S47.
6Blanshard C,millson C,Sercombe J,et al.The effects of rabeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects.Gut,1996,39(Suppl 3):A47.
7Wilder-Smith CH,Rohhss K,Nilsson-Pieschl C,et al.Esomeprazole 40mg provides improved intragastric acid control as compared with Lansoprazole 30mg and rabeprazole on human cytochrome P450 activities.DMD,2004,32:821～827.
8kromer w, Horbach S,Lubmann R. Relative efficacies of gastric, proton pump inhibitors: their clinical and pharmacological basis. Pharmacology, 1999,59:57- 77.
9Metz DC. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion, 2000,62: 73- 81.
